Considering the relatively high frequency of MET alterations in lung cancers with EGFR mutations, co-targeting EGFR and MET with either a kinase inhibitor or an antibody appears to be a logical therapeutic strategy that is currently being evaluated. The gene discussed is MET; the disease is lung carcinoma.